TY  - JOUR
T1  - WArfarin vs aspirin and afasak 2
AU  - Gulløv AL, Koefoed BG, Petersen P, et al
Y1  - 1999/05/10
N1  - 
JO  - Archives of Internal Medicine
SP  - 1010
EP  - 1010
VL  - 159
IS  - 9
N2  - 
We thank Dr Bloom for his comments about the AFASAK 2 study we published.1 As commented on by Bloom, the cumulative risk for thromboembolic events in patients treated with aspirin, 300 mg/d, in the AFASAK 2 study was very close to that for patients receiving adjusted-dose warfarin sodium internationalized normal ratio of 2:3 (3.6% vs 2.8% after 1 year and 8.4% vs 8.3% after 3, respectively). However, the corresponding event rates in patients receiving aspirin, 300 mg/d, plus warfarin sodium, 1.25 mg/d, were 7.2% and 12.8%, respectively, and in patients receiving warfarin sodium, 1.25 mg/d, 5.8% and 11.9%, respectively. By comparing the cumulative event rates, no significant difference was found (P=.67) between the 4 study groups.

SN  - 0003-9926
M3  - doi: 
UR  - http://dx.doi.org/
ER  -